Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis
Pharmacology · 2023
DOI: 10.1159/000529242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, 2023. Verfasst von Robert Krysiak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland. Hauptthemen laut MEDLINE: Hypercholesterolemia, Thyroiditis, Autoimmune, Hashimoto Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Autoimmune thyroiditis seems to be associated with increased cardiometabolic risk. Statins, the mainstay of cardiovascular risk reduction and prevention, were found to reduce thyroid antibody titers. The aim of this study was to investigate plasma markers of cardiometabolic risk in statin-treated women with thyroid autoimmunity.
Methods
We compared two matched groups of euthyroid women with hypercholesterolemia receiving atorvastatin treatment: subjects with autoimmune (Hashimoto’s) thyroiditis (group A, n = 29) and subjects without thyroid pathology (group B, n = 29). Plasma lipids, glucose homeostasis markers, as well as circulating levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine, and 25-hydroxyvitamin D were measured before atorvastatin treatment and 6 months later.
Results
At entry, both groups differed in antibody titers, insulin sensitivity, and plasma levels of uric acid, hsCRP, fibrinogen, homocysteine, and 25-hydroxyvitamin D. Atorvastatin-induced reduction in hsCRP and homocysteine, but not in total cholesterol and LDL-cholesterol, was more pronounced in group B than in group A. Only in group B, the drug decreased uric acid and fibrinogen and increased 25-hydroxyvitamin D. In group A, atorvastatin reduced insulin responsiveness.
Conclusion
The obtained results indicate that euthyroid women with Hashimoto’s thyroiditis may benefit to a lesser degree from atorvastatin treatment than other populations of women with hypercholesterolemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
- Department of Pediatrics in Bytom, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Zitieren
APA
Krysiak, R., Kowalcze, K., & Okopień, B. (2023). Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis. Pharmacology. https://doi.org/10.1159/000529242
Vancouver
Krysiak R, Kowalcze K, Okopień B. Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis. Pharmacology. 2023. doi:10.1159/000529242
BibTeX
@article{Krysiak2023,
author = {Krysiak, Robert and Kowalcze, Karolina and Okopień, Bogusław},
title = {Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis},
journal = {Pharmacology},
year = {2023},
doi = {10.1159/000529242}
}
EUVIMED